EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis

Antonio Di Francesco, Pierfelice Cutrufelli, Cecilia Chiarenza, Luca Zambuto, Carmen Concerto, Ludovico Mineo, Antonino Petralia, Marco Catalfo, Alessandro Rodolico, Myrto Samara, Stefan Leucht, Filippo Caraci und 1 weitere

European Archives of Psychiatry and Clinical Neuroscience · 2026-09 · 276 (6) · 2789-2798

DOI: 10.1007/s00406-026-02249-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, online erschienen am 28.04.2026. Verfasst von Antonio Di Francesco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Catania, Catania, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabidiol (CBD) has shown therapeutic potential as an antipsychotic in preclinical studies, although the pharmacodynamics profile remains to be fully explained. Current research focuses on CBD as an adjunctive strategy, a design that allows addressing residual symptoms while avoiding the ethical and clinical risks associated with discontinuing standard antipsychotic medication. This systematic review and meta-analysis evaluated the efficacy of CBD as an adjunctive therapy for positive and negative symptoms in schizophrenia spectrum disorders. PubMed and CENTRAL were searched up to May 14, 2025. We included randomized controlled trials (RCTs) comparing CBD augmentation to placebo in adults with these disorders. Primary outcomes were changes on the Positive and Negative Syndrome Scale (PANSS). Five RCTs were included. Meta-analysis showed a statistically significant advantage for CBD over placebo for PANSS total scores (Mean Difference, MD -1.91; 95% Confidence Interval, CI -3.726 to -0.102), positive subscale (MD -1.304; CI -1.917 to -0.692), and general subscale (MD -1.094; CI -1.57 to -0.618). No significant effect was found for the negative subscale. Dropout rates were not significantly different (Odds Ratio, OR 0.93; 95% CI 0.55 to 1.59). Heterogeneity was low across outcomes. Our findings demonstrate a statistically significant, albeit small, advantage for adjunctive CBD over placebo for total, positive, and general symptoms in schizophrenia. The lack of effect on negative symptoms suggests a targeted mechanism. Given the consistency across studies, adjunctive CBD is a promising option for specific symptom clusters, but its clinical impact requires confirmation in larger trials.

Schlagwörter

Stichwörter der Autor:innen

CBDCannabisMeta-analysisPsychosisSchizophreniaTHC

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Catania, Catania, Italy.
  • Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Department of Psychiatry, Faculty of Medicine, University of Thessaly, 41334, Larissa, Greece.
  • Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. stefan.leucht@tum.de.
  • Department of Drug and Health Sciences, University of Catania, Catania, Italy.
  • Oasi Research Institute-IRCCS, Unit of Translational Neuropharmacology and Translational Neurosciences, Troina, Italy.

Förderung

  • Technische Universität München

Zitieren

APA

Di Francesco, A., Cutrufelli, P., Chiarenza, C., Zambuto, L., Concerto, C., Mineo, L., Petralia, A., Catalfo, M., Rodolico, A., Samara, M., Leucht, S., Caraci, F., & Signorelli, M. S. (2026). Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 276(6), 2789-2798. https://doi.org/10.1007/s00406-026-02249-3

Vancouver

Di Francesco A, Cutrufelli P, Chiarenza C, Zambuto L, Concerto C, Mineo L, et al. Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. 2026;276(6):2789-2798. doi:10.1007/s00406-026-02249-3

BibTeX
@article{DiFrancesco2026,
  author = {Di Francesco, Antonio and Cutrufelli, Pierfelice and Chiarenza, Cecilia and Zambuto, Luca and Concerto, Carmen and Mineo, Ludovico and Petralia, Antonino and Catalfo, Marco and Rodolico, Alessandro and Samara, Myrto and Leucht, Stefan and Caraci, Filippo and Signorelli, Maria Salvina},
  title = {Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2026},
  volume = {276},
  number = {6},
  pages = {2789--2798},
  doi = {10.1007/s00406-026-02249-3}
}
Kostenlos starten →